Expanding the role of Src and protein-tyrosine phosphatases balance in modulating osteoblast metabolism: Lessons from mice

Biochimie

Volumn 92, Issue 4, 2010, Pages 327-332

  Zambuzzi, Willian F ^a   Milani, Renato ^a   Teti, Anna ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Inhibitors; Osteoblast; Osteoporosis; PTPs; Src

Indexed keywords

PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; STEROID RECEPTOR COACTIVATOR 1;

ALBERS SCHOENBERG DISEASE; BONE MASS; BONE METABOLISM; CELL ADHESION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MOTILITY; CELL PROLIFERATION; GENE ACTIVATION; GENE DISRUPTION; GENE EXPRESSION; HOMEOSTASIS; MOLECULAR WEIGHT; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OXIDATION REDUCTION STATE; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; UBIQUITINATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; BONE AND BONES; CELL ADHESION; CELL DIFFERENTIATION; MICE; MODELS, BIOLOGICAL; OSTEOBLASTS; OXIDATION-REDUCTION; PROTEIN TYROSINE PHOSPHATASES; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

ANIMALIA; MUS;

EID: 77649189594     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.01.002     Document Type: Short Survey

References (63)

1. Hunter T. Signaling-2000 and beyond. Cell 100 (2000) 113-127
2. Chengalvala M.V., Bapat A.R., Hurlburt W.W., Kostek B., Gonder D.S., Mastroeni R.A., and Frail D.E. Biochemical characterization of osteo-testicular protein tyrosine phosphatase and its functional significance in rat primary osteoblasts. Biochemistry 40 (2001) 814-821
3. Boutahar N., Guignandon A., Vico L., and Lafage-Proust M.H. Mechanical strain on osteoblasts activates autophosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 tyrosine sites involved in ERK activation. J. Biol. Chem. 279 (2004) 30588-30599
4. Li B., Boast S., de los Santos K., Schieren I., Quiroz M., Teitelbaum S.L., Tondravi M.M., and Goff S.P. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat. Genet. 24 (2000) 304-308
5. Zhao Y., Thomas H.D., Batey M.A., Cowell I.G., Richardson C.J., Griffin R.J., Calvert A.H., Newell D.R., Smith G.C., and Curtin N.J. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66 (2006) 5354-5362
6. Jänne P.A., Gray N., and Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8 (2009) 709-723
7. Ferreira C.V., Justo G.Z., Souza A.C., Queiroz K.C., Zambuzzi W.F., Aoyama H., and Peppelenbosch M.P. Natural compounds as a source of protein tyrosine phosphatase inhibitors: application to the rational design of small-molecule derivatives. Biochimie 88 (2006) 1859-1873
8. Rucci N., Susa M., and Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med. Chem. 8 (2008) 342-349
9. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 100 (2000) 293-296
10. Mitra S.K., and Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell. Biol. 18 (2006) 516-523
11. Levin V.A. Basis and importance of Src as a target in cancer. Cancer Treat. Res. 119 (2004) 89-119
12. Kim J.Y., Lee Y.G., Kim M.Y., Byeon S.E., Rhee M.H., Park J., Katz D.R., Chain B.M., and Cho J.Y. Src-mediated regulation of inflammatory responses by actin polymerization. Biochem. Pharmacol. (2009 Sep 19) 10.1016/j.bcp.2009.09.016 [Epub ahead of print]
13. Fincham V.J., James M., Frame M.C., and Winder S.J. Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src. EMBO J. 19 (2000) 2911-2923
14. Zambuzzi W.F., Bruni-Cardoso A., Granjeiro J.M., Peppelenbosch M.P., de Carvalho H.F., Aoyama H., and Ferreira C.V. On the road to understanding of the osteoblast adhesion: cytoskeleton organization is rearranged by distinct signaling pathways. J. Cell. Biochem. 108 (2009) 134-144
15. Soriano P., Montgomery C., Geske R., and Bradley A. Targeted disruption of the csrc proto-oncogene leads to osteopetrosis in mice. Cell 64 (1991) 693-702
16. Boyce B.F., Yoneda T., Lowe C., Soriano P., and Mundy G.R. Requirement of pp60c-Src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90 (1992) 1622-1627
17. Marzia M., Sims N.A., Voit S., Migliaccio S., Taranta A., Bernardini S., Faraggiana T., Yoneda T., Mundy G.R., Boyce B.F., Baron R., and Teti A. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J. Cell. Biol. 151 (2000) 311-320
18. Golden A., Nemeth S.P., and Brugge J.S. Blood platelets express high levels of the pp60c-Src-specific tyrosine kinase activity. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 852-856
19. Pyper J.M., and Bolen J.B. Identification of a novel neuronal C-Src exon expressed in human brain. Mol. Cell. Biol. 10 (1990) 2035-2040
20. Amling M., Neff L., Priemel M., Schilling A.F., Rueger J.M., and Baron R. Progressive increase in bone mass and development of odontomas in aging osteopetrotic c-Src-deficient mice. Bone 27 (2000) 603-610
21. Lowe C., Yoneda T., Boyce B.F., Chen H., Mundy G.R., and Soriano P. Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 485-489
22. Susva M., Missbach M., and Green J. Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?. Trends Pharmacol. Sci. 21 (2000) 489-495
23. Cooper J.A., Gould K.L., Cartwright C.A., and Hunter T. Tyr527 is phosphorylated in pp60c-Src: implications for regulation. Science 231 (1986) 1431-1434
24. Zheng X.M., Resnick R.J., and Shalloway D. A phosphotyrosine displacement mechanism for activation of Src by ptpa. EMBO J. 19 (2000) 964-978
25. Roskoski Jr. R. Src protein-tyrosine kinase structure and regulation. Biochem. Biophys. Res. Commun. 324 (2004) 1155-1164
26. den Hertog J., Pals C.E., Peppelenbosch M.P., Tertoolen L.G., de Laat S.W., and Kruijer W. Receptor protein tyrosine phosphatase alpha activates pp60c-Src and is involved in neuronal differentiation. EMBO J. 12 (1993) 3789-3798
27. Chiarugi P., Cirri P., Marra F., Raugei G., Camici G., Manao G., and Ramponi G. LMWptp is a negative regulator of insulin mediated mitotic and metabolic signaling. Biochem. Biophys. Res. Commun. 238 (1997) 676-682
28. Chiarugi P., Cirri P., Marra F., Raugei G., Fiaschi T., Camici G., Manao G., Romanelli R.G., and Ramponi G. The Src and signal transducers and activators of transcription pathways as specific targets for low molecular weight phosphotyrosine-protein phosphatase in platelet-derived growth factor signaling. J. Biol. Chem. 273 (1998) 6776-6785
29. Bucciantini M., Chiarugi P., Cirri P., Taddei L., Stefani M., Raugei G., Nordlund P., and Ramponi G. The low Mr phosphotyrosine protein phosphatase behaves differently when phosphorylated at Tyr131 or Tyr132 by Src kinase. FEBS Lett. 456 (1999) 73-78
30. Chiarugi P., Taddei M.L., Cirri P., Talini D., Buricchi F., Camici G., Manao G., Raugei G., and Ramponi G. Low molecular weight protein-tyrosine phosphatase controls the rate and the strength of NIH-3T3 cells adhesion through its phosphorylation on tyrosine 131 or 132. J. Biol. Chem. 275 (2000) 37619-37627
31. Ramponi G., and Stefani M. Structure and function of the low Mr phosphotyrosine protein phosphatases. Biochim. Biophys. Acta 341 (1997) 137-156
32. Rigacci S., Rovida E., Bagnoli S., Dello Sbarba P., and Berti A. Low M(r) phosphotyrosine protein phosphatase activity on fibroblast growth factor receptor is not associated with enzyme translocation. FEBS Lett. 459 (1999) 191-194
33. Rovida E., Rigacci S., Paccagnini A., Sbarba P.D., and Berti A. The low-molecular-weight phosphotyrosine protein phosphatase, when overexpressed, reduces the mitogenic response to macrophage colony-stimulating factor and tyrosine phosphorylation of its receptor. Biochem. Biophys. Res. Commun. 253 (1998) 300-304
34. Andersen J.N., Elson A., Lammers R., Rømer J., Clausen J.T., Møller K.B., and Møller N.P. Comparative study of protein tyrosine phosphatase-epsilon isoforms: membrane localization confers specificity in cellular signalling. Biochem. J. 354 (2001) 581-590
35. Tonks N.K., and Neel B.G. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr. Opin. Cell. Biol. 13 (2001) 182-195
36. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., and Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 117 (2004) 699-711
37. Andersen J.N., Jansen P.G., Echwald S.M., Mortensen O.H., Fukada T., Del Vecchio R., Tonks N.K., and Moller N.P. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 18 (2004) 8-30
38. Tautz L., Pellecchia M., and Mustelin T. Targeting the ptpome in human disease. Expert Opin. Ther. Targets 10 (2006) 157-177
39. Freire A.C., Aoyama H., Haun M., and Ferreira C.V. Relationship between phosphatase activity and cytotoxic effect of two protein phosphatase inhibitors, okadaic acid and pervanadate, on human myeloid leukemia cell line. J. Enzym. Inhib. Med. Chem. 18 (2003) 425-429
40. Freire A.C., de Assis C.F., Frick A.O., da Silva Melo P., Haun M., Aoyama H., Durán N., Sauer M.M., Kallás E.G., and Ferreira C.V. Influence of protein phosphatase inhibitors on HL60 cells death induction by dehydrocrotonin. Leuk. Res. 27 (2003) 823-829
41. Bispo de Jesus M., Zambuzzi W.F., Ruela de Sousa R.R., Areche C., Santos de Souza A.C., Aoyama H., Schmeda-Hirschmann G., Rodríguez J.A., Monteiro de Souza Brito A.R., Peppelenbosch M.P., den Hertog J., de Paula E., and Ferreira C.V. Ferruginol suppresses survival signaling pathways in androgen-independent human prostate cancer cells. Biochimie 90 (2008) 843-854
42. Souza A.C., Azoubel S., Queiroz K.C., Peppelenbosch M.P., and Ferreira C.V. From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase. Cell. Mol. Life Sci. 66 (2009) 1140-1153
43. Zambuzzi W.F., Granjeiro J.M., Parikh K., Yuvaraj S., Peppelenbosch M.P., and Ferreira C.V. Modulation of Src activity by low molecular weight protein tyrosine phosphatase during osteoblast differentiation. Cell Physiol. Biochem. 22 (2008) 497-506
44. Zambuzzi W.F., Yano C.L., Cavagis A.D., Peppelenbosch M.P., Granjeiro J.M., and Ferreira C.V. Ascorbate-induced osteoblast differentiation recruits distinct MMP-inhibitors: RECK and TIMP-2. Mol. Cell. Biochem. 322 (2009) 143-150
45. de Souza Malaspina T.S., Zambuzzi W.F., dos Santos C.X., Campanelli A.P., Laurindo F.R., Sogayar M.C., and Granjeiro J.M. A possible mechanism of low-molecular weight protein tyrosine phosphatase (LMW-ptp) activity modulation by glutathione action during human osteoblast differentiation. Arch. Oral Biol. 54 (2009) 642-650
46. Schinke T., Gebauer M., Schilling A.F., Lamprianou S., Priemel M., Mueldner C., Neunaber C., Streichert T., Ignatius A., Harroch S., and Amling M. The protein tyrosine phosphatase Rptpzeta is expressed in differentiated osteoblasts and affects bone formation in mice. Bone 42 (2008) 524-534
47. Mauro L.J., Olmsted E.A., Davis A.R., and Dixon J.E. Parathyroid hormone regulates the expression of the receptor protein tyrosine phosphatase, OST-ptp, in rat osteoblast-like cells. Endocrinology 137 (1996) 925-933
48. Lee K., Nichols J., and Smith A. Identification of a developmentally regulated protein tyrosine phosphatase in embryonic stem cells that is a marker of pluripotential epiblast and early mesoderm. Mech. Dev. 59 (1996) 153-164
49. Dacquin R., Mee P.J., Kawaguchi J., Olmsted-Davis E.A., Gallagher J.A., Nichols J., Lee K., Karsenty G., and Smith A. Knock-in of nuclear localised beta-galactosidase reveals that the tyrosine phosphatase Ptprv is specifically expressed in cells of the bone collar. Dev. Dyn. 229 (2004) 826-834
50. Wheeler M.A., Townsend M.K., Yunker L.A., and Mauro L.J. Transcriptional activation of the tyrosine phosphatase gene, OST-ptp, during osteoblast differentiation. J. Cell. Biochem. 87 (2002) 363-376
51. den Hertog J., Ostman A., and Böhmer F.D. Protein tyrosine phosphatases: regulatory mechanisms. FEBS J. 275 (2008) 831-847
52. Choi M.H., Lee I.K., Kim G.W., Kim B.U., Han Y.H., Yu D.Y., Park H.S., Kim K.Y., Lee J.S., Choi C., Bae Y.S., Lee B.I., Rhee S.G., and Kang S.W. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435 (2005) 347-353
53. Weibrecht I., Böhmer S.A., Dagnell M., Kappert K., Östman A., and Böhmer F.D. Oxidation sensitivity of the catalytic cysteine of the protein-tyrosine phosphatases SHP-1 and SHP-2. Free Radic. Biol. Med. 43 (2007) 100-110
54. Zhang Z.Y., and Dixon J.E. Active site labeling of the Yersinia protein tyrosine phosphatase: the determination of the pKa of the active site cysteine and the function of the conserved histidine 402. Biochemistry 32 (1993) 9340-9345
55. Peters G.H., Frimurer T.M., and Olsen O.H. Electrostatic evaluation of the signature motif (H/V)CX5R(S/T) in protein-tyrosine phosphatases. Biochemistry 37 (1998) 5383-5393
56. Lee S.R., Kwon K.S., Kim S.R., and Rhee S.G. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J. Biol. Chem. 273 (1998) 15366-15372
57. 2. J. Biol. Chem. 273 (1998) 32554-32560
58. Denu J.M., and Tanner K.G. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37 (1998) 5633-5642
59. 2. J. Biol. Chem. 277 (2002) 20336-20342
60. Jackson M.D., and Denu J.M. Molecular reactions of protein phosphatases-insights from structure and chemistry. Chem. Rev. 101 (2001) 2313-2340
61. Missbach M., Jeschke M., Feyen J., Müller K., Glatt M., Green J., and Susa M. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone 24 (1999) 437-449
62. Recchia I., Rucci N., Funari A., Migliaccio S., Taranta A., Longo M., Kneissel M., Susa M., Fabbro D., and Teti A. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 4 (2004) 65-79
63. Hannon R.A., Clack G., Rimmer M., Swaisland A., Lockton J.A., Finkelman R.D., and Eastell R. Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-Blind, placebo-controlled, multiple ascending dose phase I trial. J. Bone Miner. Res. (2009 Sep 23) 10.1359/jbmr.090830 [Epub ahead of print]